{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:33:35Z","timestamp":1787841215629,"version":"build-2784847793"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Long-term metabolic disease type 2 diabetes mellitus (T2DM) is distinguished by elevated blood glucose, insulin resistance, and drought of insulin with dyslipidemia. Oral hypoglycemic agents lower blood glucose levels as well as prevent both short-term and long-term complications such as micro\/macrovascular atherosclerosis, chronic kidney diseases, and chronic heart disease. This study aims to compare the effect of glimepiride versus teneligliptin in combination with metformin in T2DM patients attending a tertiary care hospital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>This prospective, randomized, open-label study was initiated in a tertiary care hospital after obtaining IEC approval. Written informed consent was obtained. The sample size was calculated using \u201cStatistics and sample size software.\u201d Ninety-seven patients satisfying the inclusion criteria were assigned to two groups using simple randomization with allocation 1:1. Group A received metformin + glimepiride while Group B received metformin + teneligliptin for 12 weeks. Fasting blood sugar (FBS), postprandial blood sugar (PPBS), glycated hemoglobin (HbA1c), and lipid profile were recorded at the baseline and at the end of 12 weeks. This study was conducted for 1 year. Data were analyzed using SPSS version 23.0 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Out of 97 participants (Group A: 48 and Group B: 49), Group A showed a higher reduction in FBS (48.18 \u00b1 9.64) whereas Group B showed 72.53 \u00b1 5.01, 1.74 \u00b1 0.42 of change in PPBS and HbA1c after 12 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>The study found that combining metformin with teneligliptin was better tolerated and improved glycemic control and lipid profile compared to metformin plus glimepiride.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijp.ijp_107_24","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T05:01:02Z","timestamp":1734411662000},"page":"317-321","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Effect of glimepiride versus teneligliptin in combination with metformin in type 2 diabetes mellitus patients"],"prefix":"10.4103","volume":"56","author":[{"given":"Razia Abdul","family":"Rasheed","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Chengalpattu, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Venkatraman","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Vels Medical College and Hospital, Tiruvallur, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vijayalakshmi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Chengalpattu, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. A. R.","family":"Raja","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Chengalpattu, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Senthil","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Chengalpattu, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Renugadevi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Chengalpattu, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"R1-20241217","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0001-2092(06)61065-X","article-title":"Diabetes mellitus and its chronic complications","volume":"76","author":"Bailes","year":"2002","journal-title":"AORN J"},{"key":"R5-20241217","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7748\/ns.2021.e11709","article-title":"Diabetes mellitus: An overview of the types, symptoms, complications and management","volume":"37","author":"Cloete","year":"2022","journal-title":"Nurs Stand"},{"key":"R6-20241217","doi-asserted-by":"crossref","first-page":"110708","DOI":"10.1016\/j.biopha.2020.110708","article-title":"Type II diabetes mellitus: A review on recent drug based therapeutics","volume":"131","author":"Padhi","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"R7-20241217","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1007\/s00125-017-4336-x","article-title":"Metformin: Clinical use in type 2 diabetes","volume":"60","author":"Sanchez-Rangel","year":"2017","journal-title":"Diabetologia"},{"key":"R8-20241217","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/1568026620666191224141617","article-title":"Mechanisms and characteristics of sulfonylureas and glinides","volume":"20","author":"Lv","year":"2020","journal-title":"Curr Top Med Chem"},{"key":"R9-20241217","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fendo.2020.00178","article-title":"GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: Review of head-to-head clinical trials","volume":"11","author":"Gilbert","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R10-20241217","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3389\/fphar.2018.00449","article-title":"Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"key":"R11-20241217","first-page":"1679","article-title":"Effect of teneligliptin supplementation as add on therapy to metformin in uncontrolled type 2 diabetes mellitus","volume":"5","author":"Abhijeet","year":"2017","journal-title":"Int J Adv Pharm Biol Chem"},{"key":"R12-20241217","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1007\/s13300-021-01148-1","article-title":"Efficacy and safety of switching to teneligliptin in patients with type 2 diabetes inadequately controlled with dipeptidyl peptidase-4 inhibitors: 52-week results from a prospective observational study","volume":"12","author":"Kim","year":"2021","journal-title":"Diabetes Ther"},{"key":"R13-20241217","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.2337\/dc21-S002","article-title":"2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"R14-20241217","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4103\/2230-8210.163171","article-title":"Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement","volume":"19","author":"Kalra","year":"2015","journal-title":"Indian J Endocrinol Metab"},{"key":"R16-20241217","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/DMSO.S106133","article-title":"Teneligliptin in management of type 2 diabetes mellitus","volume":"9","author":"Sharma","year":"2016","journal-title":"Diabetes Metab Syndr Obes"},{"key":"R17-20241217","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/dom.13566","article-title":"Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial","volume":"21","author":"Kim","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R18-20241217","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/dom.12293","article-title":"Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: A systematic review and meta-analysis","volume":"16","author":"Kim","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"R19-20241217","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2147\/VHRM.S33194","article-title":"Glimepiride: Evidence-based facts, trends, and observations (GIFTS). [Corrected]","volume":"8","author":"Basit","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"R20-20241217","first-page":"555869","article-title":"Efficacy and safety of teneligliptin as add on therapy in Indian type 2 diabetes mellitus T2DM patients having dyslipidemia","volume":"13","author":"Parmar","year":"2020","journal-title":"Curre Res Diabetes Obes J"},{"key":"R21-20241217","doi-asserted-by":"crossref","first-page":"692","DOI":"10.18203\/2320-6012.ijrms20200258","article-title":"A study of effectiveness of addition of drug teneligliptin to metformin, glimepiride, pioglitazone combination in type II diabetic patients","volume":"8","author":"Patil","year":"2020","journal-title":"Int J Res Med Sci"},{"key":"R22-20241217","doi-asserted-by":"crossref","first-page":"481","DOI":"10.18203\/2349-3933.ijam20191163","article-title":"Effect of teneligliptin versus metformin on glycemic control in Indian patients with newly-diagnosed, drug-na\u00efve type 2 diabetes mellitus: A 12-week randomized comparative clinical study","volume":"6","author":"Raghavan","year":"2019","journal-title":"Int J Adv Med"},{"key":"R23-20241217","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.molmet.2017.07.016","article-title":"Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease","volume":"6","author":"Baumeier","year":"2017","journal-title":"Mol Metab"},{"key":"R24-20241217","first-page":"5258","article-title":"A study to compare efficacy of metformin-glimepiride versus metformin-teneligliptin in type II diabetic patients","volume":"9","author":"Nishanth","year":"2018","journal-title":"Int J Pharm Sci Res"},{"key":"R25-20241217","doi-asserted-by":"crossref","first-page":"e00222","DOI":"10.1002\/edm2.222","article-title":"Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double-blind, placebo-controlled study","volume":"4","author":"Ji","year":"2021","journal-title":"Endocrinol Diabetes Metab"},{"key":"R26-20241217","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40261-016-0478-8","article-title":"Factors related to the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors: A systematic review and meta-analysis focusing on ethnicity and study regions","volume":"37","author":"Fujita","year":"2017","journal-title":"Clin Drug Investig"},{"key":"R27-20241217","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/cpt.692","article-title":"Ethnic difference in the pharmacodynamics-efficacy relationship of dipeptidyl peptidase-4 inhibitors between Japanese and non-Japanese patients: A systematic review","volume":"102","author":"Ito","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R28-20241217","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s00125-012-2827-3","article-title":"Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: A systematic review and meta-analysis","volume":"56","author":"Kim","year":"2013","journal-title":"Diabetologia"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_107_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:45:55Z","timestamp":1787838355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_107_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_107_24","relation":{},"ISSN":["0253-7613","1998-3751"],"issn-type":[{"value":"0253-7613","type":"print"},{"value":"1998-3751","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"2024-02-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}